GlassScriptPhysician profile
Britany D Sasser
NPI 1275100737
$4,808.77
in general payments reported to CMS, 2019-2025
31 companies · $356 in 2025
The $356 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $483 · 2022: $2,305 · 2023: $1,299 · 2024: $367 · 2025: $356.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,021.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,021.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,165.55 | 2021-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $797.20 | 2021-2025 | Airsupra, Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $713.93 | 2022-2024 | Ofev, Stiolto Respimat, Tradjenta |
| Amgen INC. | $249.44 | 2022-2025 | Tezspire, Evenity, Repatha |
| Regeneron Healthcare Solutions, INC. | $228.81 | 2021-2023 | Dupixent |
| Actelion Pharmaceuticals US, INC. | $223.97 | 2021-2023 | Opsumit |
| Takeda Pharmaceuticals U.S.A., INC. | $183.46 | 2021-2023 | Glassia |
| Grifols USA, LLC | $177.55 | 2021-2023 | Prolastin-C Liquid |
| Mylan Specialty L.P. | $170.71 | 2022-2023 | Yupelri |
| United Therapeutics Corporation | $164.94 | 2022-2023 | Tyvaso |
| Electromed, INC. | $156.27 | 2023-2025 | Smartvest |
| Medtronic, INC. | $59.46 | 2025 | Symplicity G3 |
| Ethicon INC. | $50.88 | 2022-2023 | Monarch Platform |
| Inogen, INC. | $46.36 | 2022-2023 | Inogen One G5 Oxygen Concentrator - Bluetooth, Inogen One G3 Oxygen Concentrator |
| Axsome Therapeutics, INC. | $45.70 | 2023 | Sunosi |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $44.01 | 2022-2023 | |
| Insmed, INC. | $40.54 | 2023 | Arikayce |
| Jazz Pharmaceuticals INC. | $37.21 | 2022-2023 | |
| Abbvie INC. | $35.01 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $28.33 | 2023-2024 | Xarelto, Spravato |
| Merck Sharp & Dohme LLC | $25.81 | 2021-2022 | |
| Scpharmaceuticals INC. | $23.81 | 2025 | |
| Harmony Biosciences LLC | $22.40 | 2024 | |
| Inspire Medical Systems, INC. | $18.71 | 2025 | Inspire |
| Alexion Pharmaceuticals, INC. | $18.20 | 2022 | |
| Tactile Systems Technology INC | $15.41 | 2023 | Flexitouch Plus, Entre Plus |
| Novo Nordisk INC | $15.26 | 2024 | Ozempic |
| Philips North America LLC | $14.43 | 2023 | |
| Sumitomo Pharma America, INC. | $14.30 | 2023 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $13.68 | 2023 | |
| Phathom Pharmaceuticals, INC. | $7.43 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Britany Sasser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.